Post hoc analysis of PACIFIC (660 patients, unresectable stage III NSCLC after chemoradiotherapy): with durvalumab, baseline PPI use was associated with shorter median PFS (9·4 vs 17·2 months; HR 1·57) and OS (33·0 vs 57·9 months; HR 1·66); no association with placebo.
Secondary analysisn = 660
Brunetti et al. Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial